BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 18361407)

  • 1. Cell-Surface labeling and internalization by a fluorescent inhibitor of prostate-specific membrane antigen.
    Liu T; Wu LY; Kazak M; Berkman CE
    Prostate; 2008 Jun; 68(9):955-64. PubMed ID: 18361407
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A high-affinity [(18)F]-labeled phosphoramidate peptidomimetic PSMA-targeted inhibitor for PET imaging of prostate cancer.
    Ganguly T; Dannoon S; Hopkins MR; Murphy S; Cahaya H; Blecha JE; Jivan S; Drake CR; Barinka C; Jones EF; VanBrocklin HF; Berkman CE
    Nucl Med Biol; 2015 Oct; 42(10):780-7. PubMed ID: 26169882
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of an 18F-labeled phosphoramidate peptidomimetic as a new prostate-specific membrane antigen-targeted imaging agent for prostate cancer.
    Lapi SE; Wahnishe H; Pham D; Wu LY; Nedrow-Byers JR; Liu T; Vejdani K; VanBrocklin HF; Berkman CE; Jones EF
    J Nucl Med; 2009 Dec; 50(12):2042-8. PubMed ID: 19910433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Flow cytometric detection of prostate tumor cells using chemoaffinity labels.
    Wu LY; Liu T; Grimm AL; Davis WC; Berkman CE
    Prostate; 2011 Jan; 71(1):52-61. PubMed ID: 20632319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen.
    Smith-Jones PM; Vallabahajosula S; Goldsmith SJ; Navarro V; Hunter CJ; Bastidas D; Bander NH
    Cancer Res; 2000 Sep; 60(18):5237-43. PubMed ID: 11016653
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Novel ¹¹¹In-Labeled Anti-Prostate-Specific Membrane Antigen Nanobody for Targeted SPECT/CT Imaging of Prostate Cancer.
    Chatalic KL; Veldhoven-Zweistra J; Bolkestein M; Hoeben S; Koning GA; Boerman OC; de Jong M; van Weerden WM
    J Nucl Med; 2015 Jul; 56(7):1094-9. PubMed ID: 25977460
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer.
    Benešová M; Schäfer M; Bauder-Wüst U; Afshar-Oromieh A; Kratochwil C; Mier W; Haberkorn U; Kopka K; Eder M
    J Nucl Med; 2015 Jun; 56(6):914-20. PubMed ID: 25883127
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Choy CJ; Ling X; Geruntho JJ; Beyer SK; Latoche JD; Langton-Webster B; Anderson CJ; Berkman CE
    Theranostics; 2017; 7(7):1928-1939. PubMed ID: 28638478
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure-Activity Relationship of (18)F-Labeled Phosphoramidate Peptidomimetic Prostate-Specific Membrane Antigen (PSMA)-Targeted Inhibitor Analogues for PET Imaging of Prostate Cancer.
    Dannoon S; Ganguly T; Cahaya H; Geruntho JJ; Galliher MS; Beyer SK; Choy CJ; Hopkins MR; Regan M; Blecha JE; Skultetyova L; Drake CR; Jivan S; Barinka C; Jones EF; Berkman CE; VanBrocklin HF
    J Med Chem; 2016 Jun; 59(12):5684-94. PubMed ID: 27228467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen for molecular imaging of prostate cancer.
    Hillier SM; Maresca KP; Lu G; Merkin RD; Marquis JC; Zimmerman CN; Eckelman WC; Joyal JL; Babich JW
    J Nucl Med; 2013 Aug; 54(8):1369-76. PubMed ID: 23733925
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 68Ga- and 177Lu-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies.
    Weineisen M; Schottelius M; Simecek J; Baum RP; Yildiz A; Beykan S; Kulkarni HR; Lassmann M; Klette I; Eiber M; Schwaiger M; Wester HJ
    J Nucl Med; 2015 Aug; 56(8):1169-76. PubMed ID: 26089548
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytoplasmic Localization of Prostate-Specific Membrane Antigen Inhibitors May Confer Advantages for Targeted Cancer Therapies.
    Matthias J; Engelhardt J; Schäfer M; Bauder-Wüst U; Meyer PT; Haberkorn U; Eder M; Kopka K; Hell SW; Eder AC
    Cancer Res; 2021 Apr; 81(8):2234-2245. PubMed ID: 33622696
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-prostate-specific membrane antigen liposomes loaded with 225Ac for potential targeted antivascular α-particle therapy of cancer.
    Bandekar A; Zhu C; Jindal R; Bruchertseifer F; Morgenstern A; Sofou S
    J Nucl Med; 2014 Jan; 55(1):107-14. PubMed ID: 24337602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radiolabeled monoclonal antibodies specific to the extracellular domain of prostate-specific membrane antigen: preclinical studies in nude mice bearing LNCaP human prostate tumor.
    Smith-Jones PM; Vallabhajosula S; Navarro V; Bastidas D; Goldsmith SJ; Bander NH
    J Nucl Med; 2003 Apr; 44(4):610-7. PubMed ID: 12679407
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PSA-responsive and PSMA-mediated multifunctional liposomes for targeted therapy of prostate cancer.
    Xiang B; Dong DW; Shi NQ; Gao W; Yang ZZ; Cui Y; Cao DY; Qi XR
    Biomaterials; 2013 Sep; 34(28):6976-91. PubMed ID: 23777916
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual-Modality Image-Guided Surgery of Prostate Cancer with a Radiolabeled Fluorescent Anti-PSMA Monoclonal Antibody.
    Lütje S; Rijpkema M; Franssen GM; Fracasso G; Helfrich W; Eek A; Oyen WJ; Colombatti M; Boerman OC
    J Nucl Med; 2014 Jun; 55(6):995-1001. PubMed ID: 24700882
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phosphoramidate derivatives of hydroxysteroids as inhibitors of prostate-specific membrane antigen.
    Wu LY; Do JC; Kazak M; Page H; Toriyabe Y; Anderson MO; Berkman CE
    Bioorg Med Chem Lett; 2008 Jan; 18(1):281-4. PubMed ID: 18023582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A low molecular weight PSMA-based fluorescent imaging agent for cancer.
    Chen Y; Dhara S; Banerjee SR; Byun Y; Pullambhatla M; Mease RC; Pomper MG
    Biochem Biophys Res Commun; 2009 Dec; 390(3):624-9. PubMed ID: 19818734
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A new generation of monoclonal and recombinant antibodies against cell-adherent prostate specific membrane antigen for diagnostic and therapeutic targeting of prostate cancer.
    Elsässer-Beile U; Wolf P; Gierschner D; Bühler P; Schultze-Seemann W; Wetterauer U
    Prostate; 2006 Sep; 66(13):1359-70. PubMed ID: 16894535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging.
    Eder M; Schäfer M; Bauder-Wüst U; Hull WE; Wängler C; Mier W; Haberkorn U; Eisenhut M
    Bioconjug Chem; 2012 Apr; 23(4):688-97. PubMed ID: 22369515
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.